Categories: NewsNutrition

Theralogix Launches TheraCran(R) Max: Dual-Action Defense for Urinary Tract Health

ROCKVILLE, MD / ACCESSWIRE / January 7, 2025 / Theralogix, a trusted leader in the nutritional supplement industry, proudly announces the launch of TheraCran® Max, a premium dual-action supplement designed to deliver daily urinary tract health support.* By combining content-certified cranberry extract with pure d-mannose, TheraCran Max provides a comprehensive, broad-spectrum approach to urinary health.*

TheraCran Max utilizes two scientifically backed ingredients that work in complementary ways. Each daily serving contains 40 mg of soluble proanthocyanidins (PACs) from the juice portion of a whole cranberry extract plus 1,000 mg of d-mannose. Cranberry PACs and d-mannose work in unique ways, both binding to bacteria to help flush it from the urinary tract.*

TheraCran Max is the only cranberry and d-mannose supplement independently tested and certified by NSF® International, ensuring content accuracy, purity, and safety. This rigorous third-party certification sets TheraCran Max apart in a market where assurance of quality and content accuracy are essential, but often absent.

As with all Theralogix products, TheraCran Max is manufactured in the USA in a GMP-compliant facility, spotlighting the company’s commitment to high-quality, evidence-based supplements. It is dye-free, gluten-free, and formulated specifically for anyone seeking reliable urinary tract health support.*

Theralogix is the #1 urologist-recommended supplement brand. When it comes to premium, research-backed nutritional supplements, Theralogix has set the standard for over two decades. TheraCran Max is now available for purchase on Theralogix.com and Amazon.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Contact Information

Shannon Mahon
smahon@theralogix.com
301.464.7210

SOURCE: Theralogix

View the original press release on accesswire.com

Staff

Recent Posts

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care…

2 hours ago

BlackfinBio Ltd announces the acquisition of Parkinson’s IP patent portfolio from OXB

SHEFFIELD, United Kingdom, Jan. 8, 2025 /PRNewswire/ -- BlackfinBio Ltd (BFB) a clinical stage gene therapy…

2 hours ago

Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000

LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased…

5 hours ago

PhenQ Reviews: Legit Fat Burner Supplement or Scam Weight Loss Pills?

PhenQ is a natural weight management system that targets five major areas of metabolic health,…

5 hours ago

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…

14 hours ago